{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:54:39Z","timestamp":1772135679910,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41585-021-00457-1","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T12:02:33Z","timestamp":1616760153000},"page":"323-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is delay to radical cystectomy following BCG failure oncologically safe?"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-4043","authenticated-orcid":false,"given":"Wei Shen","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"457_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000499257","volume":"14","author":"JCM Wan","year":"2020","unstructured":"Wan, J. C. M. Survival outcomes of early versus deferred cystectomy for high-grade non-muscle-invasive bladder cancer: a systematic review. Curr. Urol. 14, 66\u201373 (2020).","journal-title":"Curr. Urol."},{"key":"457_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"GV Raj","year":"2007","unstructured":"Raj, G. V. et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J. Urol. 177, 1283\u20131286 (2007).","journal-title":"J. Urol."},{"key":"457_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","volume":"47","author":"WS Tan","year":"2016","unstructured":"Tan, W. S., Rodney, S., Lamb, B., Feneley, M. & Kelly, J. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat. Rev. 47, 22\u201331 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"457_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.01.004","author":"VT Packiam","year":"2021","unstructured":"Packiam, V. T. et al. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: a multi-institution analysis. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.004 (2021).","journal-title":"Urol. Oncol."},{"key":"457_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J. Clin. Oncol. 34, 1935\u20131944 (2016).","journal-title":"J. Clin. Oncol."},{"key":"457_CR6","doi-asserted-by":"publisher","first-page":"108.e1","DOI":"10.1016\/j.urolonc.2014.02.020","volume":"33","author":"HW Herr","year":"2015","unstructured":"Herr, H. W., Milan, T. N. & Dalbagni, G. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol. Oncol. 33, 108.e1\u2013108.e4 (2015).","journal-title":"Urol. Oncol."},{"key":"457_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan, W. S. et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Gu\u00e9rin or institutional standard in patients with recurrence of non\u2013muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Gu\u00e9rin therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur. Urol. 75, 63\u201371 (2019).","journal-title":"Eur. Urol."},{"key":"457_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41585-018-0092-z","volume":"15","author":"WS Tan","year":"2018","unstructured":"Tan, W. S. & Kelly, J. D. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat. Rev. Urol. 15, 667\u2013685 (2018).","journal-title":"Nat. Rev. Urol."},{"issue":"Suppl. 15","key":"457_CR9","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1200\/JCO.2020.38.15_suppl.5041","volume":"38","author":"AV Balar","year":"2020","unstructured":"Balar, A. V. et al. Pembrolizumab (pembro) for the treatment of patients with bacillus Calmette-Gu\u00e9rin (BCG) unresponsive, high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC): over two years follow-up of KEYNOTE-057. J. Clin. Oncol. 38 (Suppl. 15), 5041 (2020).","journal-title":"J. Clin. Oncol."},{"key":"457_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian, S. A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22, 107\u2013117 (2021).","journal-title":"Lancet Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41585-021-00457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-021-00457-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-021-00457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:44:42Z","timestamp":1684604682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00457-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1038\/s41585-021-00457-1","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/ZPRZNB","asserted-by":"object"}]},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"26 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.S.T. and J.D.K. are consultants for Combat Medical. J.D.K. is chief investigator for HYMN and HIVEC-II, which are trials using hyperthermia delivery systems to treat bladder cancer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}